PAKOLA STEVE 4
4 · REGENXBIO Inc. · Filed Mar 7, 2024
Insider Transaction Report
Form 4
REGENXBIO Inc.RGNX
PAKOLA STEVE
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-05$22.25/sh+12,878$286,536→ 120,070 total - Sale
Common Stock
2024-03-05$28.36/sh−12,878$365,220→ 107,192 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-03-05−12,878→ 31,277 totalExercise: $22.25Exp: 2033-01-03→ Common Stock (12,878 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The previously granted option, representing a right to purchase a total of 44,155 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2024, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer